Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Afferon and Mundipharma collaborate on development of resiniferatoxin

May 5, 1999

U.S. patent issued to NitroMed, providing protection for MED/FSAD treatment program

April 28, 1999

Medtronic's urinary control device approved by FDA

April 28, 1999

Urethra-selective alpha1-agonists under development at Mitsui for urinary incontinence

April 27, 1999

News from FASEB: YM-905 is a bladder-specific M3 receptor antagonist

April 20, 1999

New compound for BPH in active preclinical development at Merck & Co. and Synaptic

April 20, 1999

New frontiers in gene therapy: treatment of erectile dysfunction

April 20, 1999

(+)-SNAP-6991 discovered at Synaptic and Merck as orally active, uroselective alpha1a blocker

April 5, 1999

New antimuscarinic piperidine derivative from Taisho inhibits bladder contractions

April 1, 1999

Pharmacokinetics and pharmacodynamics of VPA-985 in healthy volunteers

March 31, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...